Cancer-associated fibroblasts in non-small cell lung cancer: Recent advances and future perspectives

Non-small cell lung cancer (NSCLC) constitutes the majority of lung cancer, which is the leading cause of cancerrelated deaths in the world. Nearly 70% of NSCLC patients were diagnosed at advanced stage with only 15% of five-year survival rate. Cancer-associated fibroblasts (CAFs) are the major component of tumor microenvironment and account for almost 70% of the cells in tumor tissues. By the crosstalk with cancer cells, CAFs reprogrammed cancer cell metabolism, remodeled extracellular matrix (ECM) and created a supportive niche for cancer stem cells. CAFs lead collective invasion of tumor cells and shape tumor immune microenvironment, promoting tumor metastasis and immune escape. In this review, we have summarized the progress of studies regarding CAFs influences on NSCLC in recent five years from the aspects of cell growth, metabolism, therapy resistance, invasion and metastasis and immune suppression. We have discussed the involved mechanisms and implications for the development of anti-NSCLC therapies. The current strategies of CAFs targeting and elimination have also been generalized. Only better understanding of the molecular biology of CAFs may contribute to the development of novel anti-NSCLC strategies.

Automated summary

This review summarizes the recent progress in understanding the impact of CAFs on NSCLC over the past five years, discussing how CAFs interact with cancer cells and their effects on tumor growth, metastasis, and immune escape. The review highlights the implications for anti-NSCLC therapies, emphasizing the importance of a deeper understanding of the molecular biology of CAFs for the development of novel treatments.